News Archive

Indiana Biosciences Research Institute Names New Board Members

Indianapolis, Ind. – The Indiana Biosciences Research Institute (IBRI), a leading industry-inspired applied research institute, is pleased to announce the addition of eight members to its Board of Directors. Its...

IBRI IN THE NEWS: The Dialogue of Diabetes

Over the past 60 years, the incidence of type I diabetes in parts of the word has increased sixfold, and we don’t know why. In the Eizirik Lab at the...

IBRI RESEARCH PUBLISHED: Utilization of Electronic Health Records for the Assessment of Adiponectin Receptor Autoantibodies during the Progression of Cardio-metabolic Comorbidities

Abstact Background : Diabetes is a complex, multi-symptomatic disease whose complications drives increases in healthcare costs as the diabetes prevalence grows rapidly world-wide. Real-world electronic health records (EHRs) coupled...

IBRI RESEARCH PUBLISHED: SARS-CoV-2 receptor Angiotensin I-Converting Enzyme type 2 (ACE2) is expressed in human pancreatic ß-cells and in the human pancreas microvasculature

Abstract Increasing evidence demonstrated that the expression of Angiotensin I-Converting Enzyme type 2 (ACE2), is a necessary step for SARS-CoV-2 infection permissiveness. In the light of the recent data...

IBRI RESEARCH PUBLISHED: Beta Cell Imaging—From Pre-Clinical Validation to First in Man Testing

Abstract There are presently no reliable ways to quantify human pancreatic beta cell mass (BCM) in vivo, which prevents an accurate understanding of the progressive beta cell loss in...

IBRI IN THE NEWS: New Chief Wants to Grow IBRI's Global Reputation

Indianapolis - The new chief executive officer of the Indiana Biosciences Research Institute in Indianapolis says he wants to see the institute emerge as a global leader of innovative science...

IBRI RESEARCH PUBLISHED: Molecular Footprints of the Immune Assault on Pancreatic Beta Cells in Type 1 Diabetes

Abstract Type 1 diabetes (T1D) is a chronic disease caused by the selective destruction of the insulin-producing pancreatic beta cells by infiltrating immune cells. We presently evaluated the transcriptomic...

IBRI IN THE NEWS: IBRI Welcomes New Leader

The Indiana Biosciences Research Institute has a new leader. The applied research organization has named Dr. Alan Palkowitz President and CEO. He is a veteran in the field of drug...

IBRI RESEARCH PUBLISHED: Presumption of Innocence for Beta Cells: Why are They Vulnerable Autoimmune Targets in Type 1 Diabetes?

Abstract It is increasingly appreciated that the pathogenic mechanisms of type 1 diabetes involve both the autoimmune aggressors and their beta cell targets, which engage in a conflicting dialogue...

IBRI IN THE NEWS: IBRI Names New President and CEO

Indianapolis - The Indiana Biosciences Research Institute has named Dr. Alan Palkowitz president and chief executive officer. IBRI says the research scientist will continue his work at the Indiana University...